Each company is eligible for up to $525 million in milestone payments for the other company’s candidates, based on successful completion of regulatory and commercialization milestones, plus tiered high single- to double-digit royalties for sales and licensing of respective intellectual property. Each company will take responsibility for clinical development and commercialization of their selected candidates.Īmgen will provide Kite with an upfront payment of $60 million and fund R&D costs through the IND filing. Kite will conduct all preclinical research as well as cell manufacturing and processing through the Investigational New Drug (IND) filing. Under the agreement, a joint steering committee identified a pool of targets from which each side has preselected its own targets. The companies hope that combining Amgen’s collection of cancer targets with Kite’s T-cell engineering process will further the success of CAR T-cell therapies for cancer treatment. “Identifying targets that are uniquely expressed in cancer, but not normal tissue is the bottleneck of the entire engineered T-cell approach.” “CAR T-cell therapies have generated great excitement in cancer immunotherapy and show very promising results in patients with advanced cancers who otherwise would have no treatment options,” said Arie Belldegrun, MD, FACS, Kite’s president and chief executive officer. Amgen and Kite Pharma have announced that they will collaborate on the development of novel chimeric antigen receptor (CAR) T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy (eACT TM) platform.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |